PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy-Reference-Cited by-同舟云学术

PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy

Published:2005-05 Issue:1 Volume:62 Page:148-153
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Bates Andrew Tom,Pickles Tom,Paltiel Chuck

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference26 articles.

1. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy;Sartor;Int J Radiat Oncol Biol Phys,1997

2. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy;D’Amico;J Natl Cancer Inst,2003

3. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma;Pickles;Cancer,2002

4. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel;Int J Radiat Oncol Biol Phys,1997

5. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients;Stamey;J Urol,1989

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-specific forecasting of postradiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse;iScience;2022-11

2. Patient-specific forecasting of post-radiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse;2022-03-09

3. Mechanistic modelling of prostate-specific antigen dynamics shows potential for personalized prediction of radiation therapy outcome;Journal of The Royal Society Interface;2019-08

4. Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer;Radiotherapy and Oncology;2013-05

5. An overview of sipuleucel-T: Autologous cellular immunotherapy for prostate cancer;Human Vaccines & Immunotherapeutics;2012-04-16